Datapoint: Centene Completes PANTHERx Sale

Centene Corp. last week completed its sale of specialty pharmacy arm PANTHERx to Vistria Group, General Atlantic and Nautic Partners. Centene originally purchased the rare drug company in December 2020. The insurer said in a July 14 press release that it intends to use the windfall to “repurchase stock and the balance to reduce debt.” Centene is also in the process of selling Magellan Rx to Prime Therapeutics, with the two deals valued at $2.8 billion. Centene is currently the fourth-largest insurer in the U.S., with 20,988,628 members.

Source: AIS’s Directory of Health Plans

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Mass. Blues Adds Tufts Medicine to ‘Pay-for-Equity’ Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: AbbVie Scores Crohn’s Nod for Rinvoq

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: Supreme Court Ends Repatha-Praluent Patent Saga

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today